Ipamorelin vs CJC-1295 vs Tesamorelin: Choosing the Right GH Peptide

The growth hormone peptide market has expanded rapidly, and choosing between the available options requires understanding how each one works differently despite producing similar headline results. After coaching clients through various GH peptide protocols over the past decade, I have developed clear preferences for different situations, and the right choice depends entirely on your specific goals and risk tolerance.

Ipamorelin: The Selective GH Releaser

Ipamorelin is a growth hormone releasing peptide that stimulates the pituitary to release GH through the ghrelin receptor pathway. What makes it unique among GH peptides is its selectivity. It produces a clean GH pulse without significantly affecting cortisol, prolactin, or appetite. This selectivity is why it has become the most popular GH peptide for long-term use.

In practical use, ipamorelin produces moderate GH elevation. It is not the most potent option available, but the absence of side effects makes it suitable for extended protocols. Clients who run ipamorelin for three to six months typically report improved sleep, better recovery, enhanced skin quality, and gradual body composition improvements.

The standard protocol is 200 to 300mcg injected subcutaneously, typically before bed to align with the natural GH pulse. Some users split the dose into two daily injections, morning and evening, to create additional GH pulses throughout the day. The compound has a short half-life of about two hours, which means each injection creates a discrete pulse rather than a sustained elevation.

CJC-1295: The Sustained Amplifier

CJC-1295 is a growth hormone releasing hormone analog that works through a different receptor than ipamorelin. It stimulates the GHRH receptor on the pituitary, providing a sustained elevation of GH production capacity rather than a single acute pulse. CJC-1295 with DAC, the drug affinity complex modification, has a half-life of approximately 6 to 8 days, meaning a single injection elevates GH output for about a week.

The sustained nature of CJC-1295 with DAC is both its advantage and its concern. The advantage is convenience and consistent GH elevation without daily injections. The concern is that it blunts the natural pulsatile pattern of GH release. Instead of discrete pulses, you get a chronically elevated baseline. Some researchers believe the pulsatile pattern is important for maintaining sensitivity and preventing downregulation, though the clinical data on this point is not conclusive.

CJC-1295 without DAC, sometimes called Mod GRF 1-29, has a much shorter half-life of about 30 minutes. This version produces acute GH pulses similar to ipamorelin and is the preferred form for users who want to maintain the natural pulsatile release pattern. It is commonly combined with ipamorelin for a synergistic effect.

Tesamorelin: The Pharmaceutical-Grade Option

Tesamorelin is an FDA-approved GHRH analog originally developed for HIV-associated lipodystrophy. It has the most robust clinical data of any GH peptide, with large randomized controlled trials demonstrating significant reductions in visceral fat, improved lipid profiles, and meaningful IGF-1 elevation.

The clinical data makes tesamorelin the strongest evidence-based choice for GH peptide therapy. The FDA approval means pharmaceutical-grade sourcing is available, eliminating the purity concerns that plague the gray market peptide landscape. The tradeoff is significantly higher cost compared to research-grade ipamorelin or CJC-1295.

In my coaching practice, tesamorelin produces the most consistent results for visceral fat reduction. Clients with stubborn abdominal fat that has not responded to diet and exercise alone often see meaningful improvement on tesamorelin within 8 to 12 weeks. The effect is specific to visceral adipose tissue rather than subcutaneous fat, which makes it particularly valuable for metabolic health.

The Ipamorelin Plus CJC-1295 Combination

The most popular GH peptide protocol combines ipamorelin with CJC-1295 without DAC. The rationale is that they work through complementary receptors. CJC-1295 primes the pituitary to produce more GH by stimulating the GHRH receptor, while ipamorelin triggers the actual release through the ghrelin receptor. Together, they produce a GH pulse that is larger than either compound achieves alone. This is a textbook application of the Tony Huge Laws of Biochemistry Physics—using synergistic receptor pathways to amplify a biological signal without proportionally increasing side effects.

The standard combination protocol is 100mcg ipamorelin plus 100mcg CJC-1295 no DAC, injected subcutaneously, two to three times daily. Most commonly, injections are done on waking, post-workout, and before bed. The before-bed injection is the most important for aligning with the natural GH rhythm.

From coaching experience, the combination protocol at moderate doses produces GH and IGF-1 elevation approaching what you would see with 1 to 2 IU of pharmaceutical HGH, but at a fraction of the cost and while maintaining pulsatile release. For natty plus practitioners who want GH optimization without crossing into full pharmaceutical HGH territory, this is the protocol I recommend most frequently.

How to Choose

For simplicity and minimal side effects with moderate results, ipamorelin alone is the starting point. For maximum efficacy while maintaining pulsatile GH release, the ipamorelin plus CJC-1295 no DAC combination is the gold standard. For evidence-based visceral fat reduction with pharmaceutical-grade sourcing, tesamorelin is the premium choice. And for those who prefer oral dosing over injections, MK-677 remains the most practical GH optimization tool available, even if injectable peptides offer superior precision and control.

Interesting Perspectives

While the primary uses for these peptides are well-established, the evolving landscape of biohacking offers some unconventional angles. Some advanced practitioners are exploring “pulse timing” protocols, using short-acting peptides like ipamorelin and CJC-1295 (no DAC) not just at night, but strategically timed around workouts and fasting windows to mimic an ultra-physiological, multi-pulse GH rhythm aimed at maximizing anabolism and lipolysis simultaneously. This approach treats the endocrine system more like a precision instrument than a blunt tool.

Another perspective considers the downstream effects beyond IGF-1. The quality of sleep and deep sleep architecture improvement reported by many users of these peptides, particularly ipamorelin, may contribute significantly to their benefits—suggesting part of their “recovery” magic is mediated through superior nervous system restoration, not just direct tissue repair. Furthermore, in the context of longevity protocols, there’s a contrarian debate about whether the goal should be sustained elevation (as with CJC-1295 DAC) or amplified natural pulses. Some argue that preserving the body’s natural pulsatile rhythm and receptor sensitivity over decades is more important than achieving the highest possible IGF-1 level today, favoring the selective, pulse-based approach of ipamorelin for very long-term use.

Citations & References